<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01148173</url>
  </required_header>
  <id_info>
    <org_study_id>NHL-ZNS-Rezidiv</org_study_id>
    <nct_id>NCT01148173</nct_id>
  </id_info>
  <brief_title>High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas</brief_title>
  <official_title>Combined Systemic and Intrathecal Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation for CNS Relapse of Aggressive Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Central nervous system (CNS) relapses of aggressive lymphomas are a rare but devastating
      complication. There is no therapy standard, conventional approaches are palliative. This
      study investigates an intensive chemotherapy with CNS penetrating drugs followed by high-dose
      chemotherapy and autologous stem cell transplantation as a potentially curative approach.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Systemic and intrathecal chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined systemic and intrathecal chemotherapy followed by HD-ASCT</intervention_name>
    <description>Methotrexate Ifosfamide Cytarabine Thiotepa Liposomal cytarabine (intrathecal) Carmustine Etoposide Autologous stem cell transplantation</description>
    <arm_group_label>Systemic and intrathecal chemotherapy</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>Holoxan</other_name>
    <other_name>Depocyt</other_name>
    <other_name>Tepadina</other_name>
    <other_name>BCNU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  highly-malignant non-Hodgkins-Lymphoma, mantle-cell lymphoma or follicular lymphoma 3°

          -  CNS relapse (meningeal or/and intraparenchymal) with or without systemic lymphoma
             manifestations

          -  ECOG performance score ≤2

          -  no active infection

          -  negative HIV-serology

          -  adequate renal function (creatinine clearance &gt; 50 ml/min)

          -  adequate bone marrow function (granulocytes &gt;1500/μl, platelets &gt; 80000/μl)

          -  normal bilirubin, AST &lt; 3 x UNL

          -  negative pregnancy test

        Exclusion Criteria:

          -  newly diagnosed NHL with primary CNS involvement

          -  indolent NHL, lymphoblastic NHL or Burkitt lymphoma

          -  preceding CNS irradiation

          -  pretreatment of CNS relapse other than corticosteroids

          -  immunosuppression, concomitant immunosuppressive therapy, status after organ
             transplantation or allogenous stem cell transplantation

          -  second cancer other than basalioma or cervical carcinoma in situ within the last 5
             years

          -  unfit to receive an intensive chemotherapy

          -  pregnancy or breastfeeding

          -  known intolerance to MTX, ifosfamide, Depocyte, cytarabine, thiotepa, carmustine or
             etoposide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnieszka Korfel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Fischer, MD</last_name>
    <phone>+ 49 30 8445</phone>
    <phone_ext>4096</phone_ext>
    <email>lars.fischer@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agnieszka Korfel, MD</last_name>
    <phone>+ 49 30 8445</phone>
    <phone_ext>4096</phone_ext>
    <email>agnieszka.korfel@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Universitätsmedizin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Fischer, MD</last_name>
      <phone>+49308445</phone>
      <phone_ext>4096</phone_ext>
      <email>lars.fischer@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Agnieszka Korfel, MD</last_name>
      <phone>+49308445</phone>
      <phone_ext>4096</phone_ext>
      <email>agnieszka.korfel@charite.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>June 21, 2010</last_update_submitted>
  <last_update_submitted_qc>June 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>PD. Dr. A. Korfel</name_title>
    <organization>Charité Universitätsmedizin Berlin</organization>
  </responsible_party>
  <keyword>CNS relapse</keyword>
  <keyword>aggressive lymphoma</keyword>
  <keyword>HD-ASCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Aggression</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

